Reprint

Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action

Edited by
September 2022
206 pages
  • ISBN978-3-0365-5221-7 (Hardback)
  • ISBN978-3-0365-5222-4 (PDF)

This book is a reprint of the Special Issue Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges.

Format
  • Hardback
License
© by the authors
Keywords
microtubule acetylation; triple-negative breast cancer; anti-cancer agent; apoptosis; K562; 8-hydroxydaidzein; apoptosis; autophagy; BCR-ABL; MAPK; NF-κB; c-myc; RNA interference; siRNA; oncogene; gene silencing; expression; nanosystems; Cytochrome P450; CYP1A1; CYP1B1; CYP2W1; breast cancer; prodrug; bioprecursor; duocarmycin; phortress; AQ4N; 5-FU resistance; colorectal cancer; drug repurposing; Genomics of Drug Sensitivity in Cancer; Connectivity Map; anticancer drug; B-lactam steroid alkylators; synthetic lethality; poly (ADP-ribose) polymerase inhibitors; ovarian cancer; hybrid steroidal alkylating agents; migration; invasion; glioblastoma; CCN1; mesenchymal–amoeboid transition; biomarker; apoptosis; HepG2; Huh7; isatin sulfonamides; angiogenesis; invasion; cancer hallmarks; molecular docking; EGFR tyrosine kinase inhibitor; photon upconversion; triplet-triplet annihilation; in vivo imaging; PLGA; nanoparticles; affibody molecule; human epidermal growth factor receptor 3 (HER3); BxPC-3; emtansine; DM1; albumin binding domain; affibody drug conjugate (AffiDC); n/a